AjaDuo Update Podcast- Diabetes News & Clinical Updates

Abstarct: Introduction and Objective:  Early-onset type 2 diabetes (T2D) is associated with a more adverse cardiometabolic profile and increased cardiovascular (CV) risk. We aimed to characterize cardiovascular risk and subclinical atherosclerosis in young adults with type 2 diabetes (T2D) participating in the YOUNG DIABETES program. Methods:  Observational study including individuals with type 2...

Abstarct: Introduction and Objective:  Glucagon-like peptide-1 receptor agonists (GLP-1RA) and Sodium-glucose transporter 2 inhibitors (SGLT2i) are crucial components of type 2 diabetes care, especially for adults with Cardio-vascular disease (CVD) or Diabetic kidney disease (DKD). However, early adoption of Glucagon-like peptide-1 receptor agonists GLP-1RA and SGLT2i remains low. Our aim was to e...

Abstarct: Introduction and Objective:  Despite cardiovascular benefits of Sodium-glucose cotransporter 2 inhibitors (SGLT2i), treatment persistence is suboptimal in routine clinical practice. We investigated whether longer treatment durations offer greater cardiovascular benefits. Methods:  We used nationwide healthcare data of South Korea (2012-2023) to emulate a target trial comparing following...

Abstarct: Introduction and Objective:  We previously showed that Sodium–Glucose Cotransporter 2 Inhibitors  (SGLT2 inhibitors) stimulate endogenous glucose production, offsetting their glucosuria-induced glucose lowering action, and that this effect is not explained by changes in plasma glucose, insulin, or glucagon concentration using a pancreatic clamp. To investigate the impact of Empagliflozin...

Objective: Over 99% of the EMPA-REG OUTCOME trial participants had established cardiovascular disease (CVD). We aimed to investigate effectiveness and safety outcomes among patients with type 2 diabetes (T2D) initiating empagliflozin vs dipeptidyl peptidase-4 inhibitor (DPP-4i) across the broad spectrum of cardiovascular risk. Methods: In a population-based cohort study we identified 39,072 pairs...

Introduction: Diabetes mellitus (DM) is a chronic metabolic disorder marked by persistent hyperglycemia. While HbA1c has traditionally been used to assess glycemic control, growing evidence highlights glycemic variability (GV) and Time in Range (TIR) as more precise indicators of glucose fluctuations, which are linked to diabetic complications, especially chronic kidney disease (CKD). Emerging com...

Background : Sodium-glucose cotransporter (SGLT) 2 inhibitors attenuate fasting glomerular hyperfiltration in people with type 2 diabetes (T2D). However, Sodium-glucosecotransporter 2-inhibition increases glucagon levels, which facilitate postprandial hyperfiltration. The impact of Sodium-glucose cotransporter 2 inhibition on protein-related hyperfiltration and postprandial (intra) kidney haemodyn...

Introduction: Diabetes mellitus is a chronic condition that requires consistent self management to prevent complications and maintain quality of life. This meta-analysis estimated the pooled prevalence of various self-care components in Indian populations with diabetes and their regional distribution. Methods: A literature search was conducted for studies published between January 2014 and Novembe...

Objective : This study aimed to compare the effects of empagliflozin-metformin versus empagliflozin- linagliptin combination therapy on cardiovascular parameters and anemia in patients with type 2 diabetes mellitus (T2DM). Study Design and setting: An analytical study was conducted over 12 weeks at National Medical Centre Hospital, Karachi. Methodology: T2DM patients were randomly assigned to eith...

Background : Diabetics with coronavirus disease 2019 (COVID-19) manifest more adverse clinical outcomes with elevated rates of death. It has been suggested that the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pathway of entrance into the host cell might be assisted bydipeptidyl peptidase-4 (DPP4), leading to inflammation and cytokine storm, with replication into the airways and un...

Introdution: Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) are highly interconnected, impacting global health. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) offer promising benefits for glycemiccontrol, cardiovascular health, and kidney protection. This review compares their effectiveness in enhancing kidney function a...

Background : Diabetes is a major public health concern in India, contributing significantly to morbidity and mortality. With variations in disease burden across states, a detailed understanding of trends in incidence, prevalence, and Disability Adjusted Life Years (DALYs) is essential for targeted interventions. Methods : This study utilized Global Burden of Disease (GBD) data from 1990 to 2021 to...

Abstract Background: Mounting evidence indicates that Type 2 diabetes mellitus (T2DM) is a public healthchallenge globally, and its occurrence is anticipated to surge in the forthcoming years. Dipeptidyl peptidase‐4 (DPP‐4) serves as a target for its treatment, with its inhibitors effectively preserving the levels of glucose‐dependentinsulinotropic peptide and glucagon‐like peptide 1(GLP‐1). This...

Abstract Aims: Guidelines for type 2 diabetes recommend add-on agents when metformin alone fails to provide adequate glycaemic control. However, early combination therapy may benefit health outcomes. We conducted a systematic review and meta-analysis to investigate this question. Methods: We searched MEDLINE and Cochrane CENTRAL (up to July 2012) without language restrictions. We sought randomized...

Abstract Importance : Sodium-glucose cotransporter 2 (SGLT2) inhibitors favorably affect cardiovascular (CV) and kidney outcomes; however, the consistency of outcomes across the class remains uncertain. Objective : To perform meta-analyses that assess the CV and kidney outcomes of all 4 available SGLT2 inhibitors in patients with type 2 diabetes. Study Selection : One hundred forty-five records we...

Abstract Introduction and Objective: To analyze the efficacy, safety and tolerability of SGLT2i and DPP-4i combination vs placebo as add-on or initial therapy in Asian patients with T2DM as available data is heterogenous in Asian population. Methods: Database like MEDLINE, Embase, and Cochrane review was searched until August 2023 to identify trials evaluating the efficacy and safety of combinatio...

Welcome to AjaDuo Update Podcast – your go-to source forconcise and clinically relevant updates in diabetes care. In this introductory episode, discover what this channeloffers—quick summaries of the latest research, treatment insights, and expertperspectives to support better diabetes management. Follow now and stay updated with every episode.